At the 2nd reading of the French bioethics bill, the Senate made significant modifications, removing several clauses which had provoked strong public dissent. Article 1, allowing ART without any medical reason for couples of women or any single woman, was finally...
Toutes les actualités "Bioethics Law"
[Press Release]: The French Are Still Deeply Divided on Controversial Bioethics Bill
Alliance VITA welcomes the vote of the bioethics bill by the Senate who left out the clauses provoking dissension and shattering bioethical boundary lines. Refusing ART without any medical reason amply illustrates the divergent viewpoints about this provision which is...
French Senate Special Committee on Bioethics: Some Success Albeit Mixed
In early February, the French Senate will continue to examinate the bioethics bill at second reading. The latest version of the bill produced by the Assembly was amended by the Special Committee, without achieving ethical relevance. This latest version amply...
[Press Release] French Bioethics Bill: Alliance VITA Denounces the Government’s Inconsiderate Obstinacy
When they heard that the debate on bioethics will resume as early as January 19th in the Bioethics Committee, Alliance VITA denounces the inconsiderate rush job that President Macron and Prime Minister Castex intend to impose on the Senators. While France is facing an...
March for the children : Press Conference held August 26, 2020
Following the adoption at 2nd reading, on August 1, of the bioethics bill by the National Assembly, a press conference by the Marchons Enfants collective! was held on August 26, 2020 in Paris. Caroline Roux, Deputy General Delegate of Alliance VITA, took part in this...
[Press Release] Alliance VITA Denounces the Abortion Rider on the Bioethics Bill
Alliance VITA denounces the hastily adopted abortion rider, tagged on to the French bioethics bill, and examined in the middle of the night. It would obviate existing abortion laws, by attaching the unverifiable criterion of "psychosocial distress". If the bill is...